{"title":"Finerenone for chronic kidney disease in type 2 diabetes","authors":"S. Chaplin","doi":"10.1002/psb.2072","DOIUrl":null,"url":null,"abstract":"Finerenone (Kerendia) is a mineralocorticoid‐receptor antagonist for the treatment of chronic kidney disease in patients with type 2 diabetes. This article discusses its indications, efficacy and adverse effects.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"14 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2072","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Finerenone (Kerendia) is a mineralocorticoid‐receptor antagonist for the treatment of chronic kidney disease in patients with type 2 diabetes. This article discusses its indications, efficacy and adverse effects.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
